Experienced in Non-Alcoholic Fatty Liver Disease

Johan Hoffstedt

Karolinska Institutet
Huddinge, AB, SE 
Experienced in Non-Alcoholic Fatty Liver Disease
Karolinska Institutet
Huddinge, AB, SE 
OverviewLocationsClinical Research

Overview

Johan Hoffstedt practices in Huddinge, Sweden. Mr. Hoffstedt is rated as an Experienced expert by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes (T2D), Obesity, Maturity Onset Diabetes of the Young, and Gastric Bypass.

His clinical research consists of co-authoring 10 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Non-Alcoholic Fatty Liver Disease.

Gender
Male

Locations

Karolinska Institutet
Huddinge, AB, Sweden
Other Locations
Stockholm, AB, Sweden

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D
Enrollment Status: Completed
Publish Date: May 01, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

10 Total Publications

A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis.
A personalized treatment program in persons with type 2 diabetes is associated with a reduction in liver steatosis.
Journal: European journal of gastroenterology & hepatology
Published: August 16, 2020

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Hoffstedt's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile